Phase 4 N=300 Randomized Double-blind Other

Clinical Study of Lipoic Acid on Ischemic Heart Failure

Ischemic Heart Failure

Bottom Line

View on ClinicalTrials.gov: NCT03491969 ↗

Enrolled (actual)

300

Serious AEs

9.0%

Results posted

Jul 2025

Primary outcome: Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Alpha-Lipoic Acid(α-LA) (Drug); Placebos (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Shanghai Zhongshan Hospital
Primary completion: Feb 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants That Had First Occurrence of the Composite Endpoint	32; 40	—

Summary

The study will evaluate the efficacy of alpha-lipoic acid(α-LA) on mortality in patients with ischemic heart failure (NYHA Class II - IV and EF =< 50%).

Eligibility Criteria

Inclusion Criteria

patients ≥ 18 years of age, male or female.
Patients with a diagnosis of AMI (>30 days) according to the global definition. ③Patients with a diagnosis of CHF (NYHA class II-IV) and reduced ejection fraction (EF = 5.2 mmol/L.

⑨ Pregnant women or women preparing for birth.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03491969). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.